{"nctId":"NCT02607800","briefTitle":"Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral Therapy","startDateStruct":{"date":"2015-11-16","type":"ACTUAL"},"conditions":["Hepatitis C"],"count":943,"armGroups":[{"label":"SOF/VEL/VOX","type":"EXPERIMENTAL","interventionNames":["Drug: SOF/VEL/VOX"]},{"label":"SOF/VEL 12 weeks","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: SOF/VEL"]}],"interventions":[{"name":"SOF/VEL/VOX","otherNames":["GS-7977/GS-5816/GS-9857","Vosevi®"]},{"name":"SOF/VEL","otherNames":["GS-7977/GS-5816","Epclusa®"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Willing and able to provide written informed consent\n* HCV RNA ≥ 10\\^4 IU/mL at screening\n* Chronic HCV infection (≥ 6 months)\n* HCV treatment naive or treatment experienced with an interferon (IFN)-based regimen\n* Use of protocol specified methods of contraception\n\nKey Exclusion Criteria:\n\n* Current or prior history of clinically significant illness that may interfere with participation in the study\n* Screening ECG with clinically significant abnormalities\n* Laboratory parameters outside the acceptable range at screening\n* Pregnant or nursing female\n* Chronic liver disease not caused by HCV\n* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)","description":"SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ) at 12 weeks after stopping study treatment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","spread":null},{"groupId":"OG001","value":"98.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Permanently Discontinue Study Drug Due to an Adverse Event","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)","description":"SVR4 and SVR 24 were defined as HCV RNA \\< LLOQ at 4 and 24 weeks after stopping study treatment, respectively.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.4","spread":null},{"groupId":"OG001","value":"98.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.0","spread":null},{"groupId":"OG001","value":"98.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HCV RNA < LLOQ On Treatment","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","spread":null},{"groupId":"OG001","value":"22.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.9","spread":null},{"groupId":"OG001","value":"61.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92.4","spread":null},{"groupId":"OG001","value":"92.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.2","spread":null},{"groupId":"OG001","value":"99.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"99.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HCV RNA","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.23","spread":"0.689"},{"groupId":"OG001","value":"-4.24","spread":"0.679"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.75","spread":"0.747"},{"groupId":"OG001","value":"-4.77","spread":"0.646"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.95","spread":"0.750"},{"groupId":"OG001","value":"-4.99","spread":"0.656"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.99","spread":"0.754"},{"groupId":"OG001","value":"-5.03","spread":"0.655"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"-5.03","spread":"0.656"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Virologic Failure","description":"Virologic failure was defined as:\n\n* On-treatment virologic failure:\n\n  * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or\n  * Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n  * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)\n* Virologic relapse:\n\n  * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at last on-treatment visit","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":null},{"groupId":"OG001","value":"0.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":15,"n":501},"commonTop":["Headache","Fatigue","Diarrhoea","Nausea","Asthenia"]}}}